Bridge Medicines
About Bridge Medicines
Bridge Medicines is a pioneering drug-discovery company focused on advancing promising early technologies in major academic institutions from human proof-of-concept to clinical development. Launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical Company Ltd., in partnership with Deerfield Management and Bay City Capital, Bridge Medicines is a groundbreaking initiative that provides an unbroken, fully funded and professionally staffed path from discovery to drug candidate.YEAR FOUNDED:
October 2016
LEADERSHIP:
CEO: William J. Polvino
5 articles about Bridge Medicines
-
Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers
7/28/2021
Bridge Medicines and Cornell University announced an exclusive license agreement to develop UBR5 Inhibitors for the treatment of certain difficult-to-treat cancers such as triple-negative breast cancer.
-
Bridge Medicines Announces Additional Funding of $10 Million from Inside Investors
11/12/2020
Bridge Medicines receives $10 million capital infusion from investors Takeda Pharmaceutical Company Ltd., Bay City Capital, and Deerfield
-
Bridge Medicines Enters Agreement with Memorial Sloan Kettering to Develop Kidney-Specific Delivery Platform for the Treatment of Acute Kidney Injury
7/23/2018
Bridge Medicines announced today an agreement with Memorial Sloan Kettering (MSK) to develop a platform designed to deliver drugs specifically to the kidney.
-
Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development
3/14/2018
Project Originated at Rockefeller University and Graduated From Tri-Institutional Therapeutics Discovery Institute
-
Bridge Medicines Taps Ex-Veloxis Pharma Head as New CEO
3/27/2017